Market Overview

Sarcoma is a rare type of cancer which develops from the transformation of mesenchymal cells. Sarcoma is a major type of cancer of bone, fats, skin, soft tissues, and breast and one such uncommon type of soft tissue cancer is called as angiosarcoma. Agniosarcoma develops in the cells of a blood vessels and can occur in any part of body.

This tumor involves rapidly proliferating cancerous cells developed from mesenchymal or endothelial sources and develop blood filled channels. The major causes of the condition are not discovered, however, lymphederma is considered as a key propeller of the angiosarcoma tumor.

Angiosarcoma treatment involves a team of multidisciplinary medical team which includes surgeons, oncologists, and other medical professionals. Tests such as CT and MRI scan, PET, and biopsy tests are widely used for the effective diagnosis of angiosarcoma. The condition is primarily treated with surgical intervention by entirely removing the tumor from the site.

Other angiosarcoma treatment includes chemotherapy and radiotherapy. The global angiosarcoma treatment market is likely to grow in the future period with the rising research and development in the field of cancer.

COVID-19 pandemic has caused a disturbance in almost all the industries. The outbreak has brought on many aspects, like falling business assurance, uncertainty about future, massive slowing of the supply chain, and others. The coronavirus pandemic has also negatively affected the angiosarcoma treatment market.

Due to the coronavirus, the flow of patients into the hospitals and clinics have been reduced which has led to decline in the surgeries, chemotherapies and radiotherapies. There has been a disruption in the supply of APIs used in making sarcoma drugs which is turn is hampering the angiosarcoma treatment market.

As the incidence rate for this disease is low, with angiosarcoma contributing to 1-2% towards sarcoma cases, the increasing number of cancer cases is expected to create a highly conducive environment for growth of the angiosarcoma treatment market.

According to the European Medicines Agency stats in January 2017, approximately 3.5 in 10,000 people suffered from angiosarcoma in Europe, in 2016, while in the U.S., angiosarcoma accounted for only 0.7% of cancer cases, making it a rare type of cancer.

Since, the condition is rare, very few companies are investing in research and development, which leads to increased cost of drugs, making it as a major factor hampering the angiosarcoma treatment market growth. However, considering the expected rise in incidence of the disease in the future period, the global angiosarcoma treatment market is expected to witness the entry of various new players.

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Get FREE Report Sample

Segmentation

Based on the treatment type	Chemotherapy Immunotherapy
Based on the location of instigation	Hemangiosarcoma Lymphangiosarcoma
Based on the end-user	Hospitals Cancer Treatment Centres Ambulatory Surgical Centres

Based on the treatment type, chemotherapy segment is expected to hold a major share in the angiosarcoma treatment market, since, it is considered more effective option to treat angiosarcoma.

Based on the location of instigation, hemangiosarcoma is likely to dominate the global angiosarcoma treatment market due to its higher prevalence rate than lymphangiosarcoma. Based on the end-user, hospitals segment is expected to be the most profitable segment in the global angiosarcoma treatment market due to the advanced medical facilities and larger number of patients flow in the hospitals.

North America accounts for the largest share in the global angiosarcoma treatment market and is expected to maintain its position during the forecast period due the major research and development activities carried out in the region. North America is expected to be followed by Europe in the global angiosarcoma treatment market due to the rising healthcare infrastructure, growing awareness about available treatments, and availability of affordability of drugs in the region.

Asia Pacific is expected to have a significant growth in the global angiosarcoma treatment market due the rising advancements in healthcare whereas the Middle East & Africa expected to be the least profitable market due to less advanced medical facilities.

The key participants operating in the global angiosarcoma treatment market are: Pfizer Inc., Amgen Inc., Genetech, Inc., Sanofi S.A., Bayer AG, Johnson & Johnson, and Others.